A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013
Completed
- Conditions
- Immune Thrombocytopenia
- Registration Number
- NCT01974232
- Lead Sponsor
- Weill Medical College of Cornell University
- Brief Summary
This is a retrospective analysis of children (≤21years old) who received clinical treatment with either Romiplostim or Eltrombopag at 2 medical centers from 2009-2013. The children included in this study were from Weill Medical College of Cornell University, New York, New York and Children's Hospital Orange County, Orange, California
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
- All patients in this study had received prior treatments before the start of TPO treatment including corticosteroids, IVIG, IV anti-D, and/or Rituximab.
Exclusion Criteria
- Children who do not have ITP
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Platelet count greater than or = to 50,000 on two consecutive weeks
- Secondary Outcome Measures
Name Time Method An increase in platelets greater than or = to 20,000 over baseline. On two consecutive weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of romiplostim and eltrombopag in pediatric immune thrombocytopenia?
How does romiplostim compare to eltrombopag in treating immune thrombocytopenia in children under 21 years old?
Which biomarkers correlate with treatment response to romiplostim or eltrombopag in pediatric ITP patients?
What are the long-term adverse event profiles of romiplostim and eltrombopag in children with immune thrombocytopenia?
Are there combination therapies involving romiplostim or eltrombopag for refractory immune thrombocytopenia in pediatric populations?
Trial Locations
- Locations (1)
Weill Cornell Medical College
🇺🇸New York, New York, United States
Weill Cornell Medical College🇺🇸New York, New York, United States